Bris­tol My­ers scraps gene ther­a­py deal with uniQure for car­dio­vas­cu­lar dis­eases

Bris­tol My­ers Squibb is hit­ting the ex­it on a col­lab­o­ra­tion with a gene ther­a­py biotech.

The Big Phar­ma com­pa­ny will no longer part­ner with uniQure on find­ing new treat­ments for car­dio­vas­cu­lar dis­eases, the biotech re­port­ed to the SEC last week, fol­low­ing a rocky re­la­tion­ship that saw the pair break off an ear­li­er agree­ment — be­fore com­ing back to the ta­ble. The deal will of­fi­cial­ly ter­mi­nate on Feb. 21, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER